Glasdegib (GLAS) plus low-dose cytarabine (LDAC) in AML or MDS: BRIGHT AML 1003 final report and four-year overall survival (OS) follow-up.

Michael Heuser,Tadeusz Robak,Pau Montesinos,Brian Leber,Walter Fiedler,Daniel A. Pollyea,Andrew Brown,Ashleigh OConnell,Wendy Ma,Geoffrey Chan,Jorge E. Cortes

Glasdegib (GLAS) plus low-dose cytarabine (LDAC) in AML or MDS: BRIGHT AML 1003 final report and four-year overall survival (OS) follow-up.

2020

Michael Heuser
Tadeusz Robak
Pau Montesinos
Brian Leber
Walter Fiedler
Daniel A. Pollyea
Andrew Brown
Ashleigh OConnell
Wendy Ma
Geoffrey Chan
Jorge E. Cortes

7509Background: In newly diagnosed AML or high-risk MDS, primary analysis of the randomized phase 2 BRIGHT AML 1003 trial (data cutoff Jan 2017) showed superior OS for GLAS+LDAC vs LDAC alone. The ...

Keywords:

Oncology
overall survival
Pathology
low dose cytarabine
Internal medicine
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations